Molecular targets in melanoma: Time for 'ethnic personalization

Expert Review of Anticancer Therapy

Volumn 12, Issue 5, 2012, Pages 601-608

  Morita, Shane Y ^a,b   Markovic, Svetomir N ^c  

^a QUEEN S MEDICAL CENTER   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c MAYO CLINIC   (United States)

Author keywords

BRAF; c KIT; ethnic personalization; melanoma; molecular profiling; NRAS; targeted therapy; vemurafenib

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; DACARBAZINE; DASATINIB; EVEROLIMUS; GEFITINIB; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MASITINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NILOTINIB; PACLITAXEL; PROTEIN TYROSINE KINASE; SELUMETINIB; SORAFENIB; TEMOZOLOMIDE; TEMSIROLIMUS; VEMURAFENIB;

ADVANCED CANCER; AFRICAN AMERICAN; ASIAN; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CAUCASIAN; CHEMOSENSITIVITY; CHINESE; COHORT ANALYSIS; DIGESTIVE SYSTEM TUMOR; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; ETHNIC DIFFERENCE; ETHNIC GROUP; ETHNICITY; EXON; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HISPANIC; HUMAN; JAPANESE; KOREAN; MELANOMA; METASTASIS POTENTIAL; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MONOTHERAPY; NONHUMAN; ONCOGENE; ONCOGENE BRAF; ONCOGENE C KIT; ONCOGENE NRAS; OVERALL SURVIVAL; PERSONALIZED MEDICINE; POPULATION GENETICS; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TREATMENT RESPONSE; UNITED STATES;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INDIVIDUALIZED MEDICINE; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; SIGNAL TRANSDUCTION;

EID: 84861316355     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.39     Document Type: Review

References (60)

1. Ries LA, Wingo PA, Miller DS et al. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer. Cancer 88, 2398-2424 (2000).
2. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27(36), 6199-6206 (2009).
3. Berwick M, Erdei E, Hay J. Melanoma epidemiology and public health. Dermatol. Clin. 27, 205-214, viii (2009).
4. Cress RD, Holly EA. Incidence of cutaneous melanoma among non-Hispanic whites, Hispanics, Asians, and blacks: an analysis of California Cancer Registry data, 1988-93. Cancer Causes Control 8(2), 246-252 (1997).
5. Hu S, Parmet Y, Allen G et al. Disparity in melanoma: a trend analysis of melanoma incidence and stage at diagnosis among whites, Hispanics, and blacks in Florida. Arch. Dermatol. 145(12), 1369-1374 (2009).
6. Johnson D, Yamane S, Morita S et al. Malignant melanoma in non-Caucasians: experience from Hawaii. Surg. Clin. N. Am. 83, 275-282 (2003).
7. Cormier JN, Xing Y, Ding M et al. Ethnic differences among patients with cutaneous melanoma. Arch. Intern. Med. 166(17), 1907-1914 (2006).
8. Curtin JA, Fridlyand J, Kageshita T et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353(20), 2135-2147 (2005).
9. Ashman LK. The biology of stem cell factor and its receptor c-KIT. Int. J. Biochem. Cell. Biol. 31, 1037-1051 (1999).
10. Funasaka Y, Boulton T, Cobb M et al. c-KIT-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is downregulated in melanomas. Mol. Biol. Cell 3(2), 197-209 (1992).
11. Natali PG, Nicotra MR, Sures I et al. Expression of c-KIT receptor in normal and transformed human nonlymphoid tissues. Cancer Res. 52, 6139-6143 (2002).
12. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24(26), 4340-4346 (2006).
13. Smalley KS, Sondak VK, Weber JS. c-KIT signaling as the driving oncogenic event in subgroups of melanomas. Histol. Histopathol. 24(5), 643-650 (2009).
14. Ugurel S, Hildenbrand R, Zimpfer A et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer 92(8), 1398-1405 (2005).
15. Wyman K, Atkins MB, Prieto V et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 106(9), 2005-2011 (2006).
16. Hodi FS, Friedlander P, Corless CL et al. Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. 26(12), 2046-2051 (2008).
17. Lutzky J, Bauer J, Bastian BC. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res. 21(4), 492-493 (2008).
18. Carvajal RD, Chapman PB, Wolchok JD et al. A Phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KIT. J. Clin. Oncol. 27(Suppl.), 15s (2009) (Abstract 9001).
19. Carvajal RD, Antonescu CR, Wolchok JD et al. KIT as a therapeutic target in metastatic melanoma. JAMA 305(22), 2327-2334 (2011).
20. Meier F, Busch S, Lasithiotakis KG et al. Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment. Br. J. Dermatol. 156, 1204-1213 (2007).
21. Ball NJ, Yohn JJ, Morelli JG et al. RAS mutations in human melanoma: a marker of malignant progression. J. Invest. Dermatol. 102, 285-290 (1994).
22. Devitt B, Liu W, Salemi R et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 24(4), 666-672 (2011).
23. Sweet RW, Yokoyama S, Kamata T et al. The product of RAS is a GTPase and the T24 oncogenic mutant is deficient in this activity. Nature 311(5983), 273-275 (1984).
24. Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J. Invest. Dermatol. 122(2), 342-348 (2004).
25. Flaherty K, Puzanov I, Sosman J et al. Phase I study of PLX 4032: BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. 27(Suppl.), 15 (2009).
26. Chapman PB, Hauschild A, Robert C et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011).
27. Eisen T, Ahmad T, Flaherty KT et al. Sorafenib in advanced melanoma: a Phase II randomized discontinuation trial analysis. Br. J. Cancer 95, 581-586 (2006).
28. Hauschild A, Agarwala SS, Trefzer U et al. Results of a Phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27, 2823-2830 (2009).
29. Flaherty KT, Lee S, Schuchter LM et al. Final results of E2603: a double-blind, randomized Phase III trial comparing carboplatin/paclitaxel with or without sorafenib in metastatic melanoma. J. Clin. Oncol. 28(7S), 8511 (2010).
30. Ribas A, Kim KB, Schuchter LM et al. BRIM-2: an open-label, multicenter Phase II study of vemurafenib in previously treated patients with BRAF V600E mutation positive melanoma. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 8509).
31. Nazarian R, Shi H, Wang Q et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973-977 (2010).
32. Johannessen CM, Boehm JS, Kim SY et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968-972 (2010).
33. Solit DB, Garraway LA, Pratilas CA et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
34. Wagle N, Emery C, Berger MF et al. Dissecting therapeutic resistance to RAFinhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29(22), 3085-3096 (2011).
35. Reiling JH, Sabatini DM. Stress and mTORture signaling. Oncogene 25, 6373-6383 (2006).
36. Dai D, Martinka M, Li G. Prognostic significance of activated Akt expression in melanoma: a clinico-pathologic study of 292 cases. J. Clin. Oncol. 23(7), 1473-1482 (2005).
37. Stahl JM, Sharma A, Cheung M et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64(19), 7002-7010 (2004).
38. Curtin JA, Stark MS, Pinkel D, Hayward NK, Bastian BC. PI3-kinase subunits are infrequent somatic targets in melanoma. J. Invest. Dermatol. 126(7), 1660-1663 (2006).
39. Dronca RS, Perez DG, Allred J et al. N0675: NCCTG Phase II study of TMZ and RAD001 therapy for metastatic melanoma. J. Clin. Oncol. 28(Suppl.), 15s (2010) (Abstract 8572).
40. Hainsworth JD, Infante JR, Spigel DR et al. Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a Phase 2 trial of the Sarah Cannon Oncology Research Consortium. Cancer 116(17), 4122-4129 (2010).
41. Akslen LA, Puntervoll H, Bachmann IM et al. Mutation analysis of the EGFR-NRAS546 pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res. 18(1), 29-35 (2008).
42. Maldonado JL, Fridlyand J, Patel H et al. Determinants of BRAF mutations in primary melanomas. J. Natl Cancer Inst. 95(24), 1878-1890 (2003).
43. Sasaki Y, Niu C, Makino R et al. BRAF point mutations in primary melanoma show different prevalences by subtype. J. Invest. Dermatol. 123(1), 177-183 (2004).
44. Takata M, Goto Y, Ichii N et al. Constitutive activation of the mitogen-activated protein kinase signaling pathway in acral melanomas. J. Invest. Dermatol. 125(2), 318-322 (2005).
45. Terada T. Low incidence of KIT gene mutations and no PDGFRA gene mutations in primary cutaneous melanoma: an immunohistochemical and molecular genetic study of Japanese cases. Int. J. Clin. Oncol. 15(5), 453-456 (2010).
46. Yun J, Lee J, Jang J et al. KIT amplification and gene mutations in acral/mucosal melanoma in Korea. APMIS 119(6), 330-335 (2011).
47. Cho JH, Kim KM, Kwon M, Kim JH, Lee J. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest. New Drugs doi:10.1007/s10637-011- 9763-9 (2011) (Epub ahead of print).
48. Chi Z, Li S, Sheng X, Si L, Cui C, Han M, Guo J. Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases. BMC Cancer 11, 85 (2011).
49. Si L, Kong Y, Xu X et al. Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur. J. Cancer 48(1), 94-100 (2012).
50. Ellerhorst JA, Greene VR, Ekmekcioglu S et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin. Cancer Res. 17(2), 229-235 (2011).
51. Akslen LA, Angelini S, Straume O et al. BRAF and NRAS mutations are frequent in nodular melanoma but are not associated with tumor cell proliferation or patient survival. J. Invest. Dermatol. 125(2), 312-317 (2005).
52. Qi RQ, He L, Zheng S et al. BRAF exon 15 T1799A mutation is common in melanocytic nevi, but less prevalent in cutaneous malignant melanoma, in Chinese Han. J. Invest. Dermatol. 131(5), 1129-1138 (2011).
53. Kong Y, Si L, Zhu Y et al. Large-scale analysis of KIT aberrations in Chinese patients with melanoma. Clin. Cancer Res. 17(7), 1684-1691 (2011).
54. Guo J, Si L, Kong Y et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-KIT mutation or amplification. J. Clin. Oncol. 29(21), 2904-2909 (2011).
55. Cohen MH, Dagher R, Griebel DJ et al. US Food and Drug Administration drug approval summaries: imatinib mesylate, mesna tablets, and zoledronic acid. Oncologist 7(5), 393-400 (2002).
56. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002).
57. Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat. Rev. Drug Discov. 10(11), 811-812 (2011).
58. Jim SY, On S, Lum CA et al. Acral lentiginous melanoma in Hawaii: characterization of the mTOR pathway in the non-Caucasian population. J. Clin. Oncol. 29(Suppl.) (2011) (Abstract 8592).
59. Fukuoka M, Yano S, Giaccone G et al. Multi-institutional randomized Phase II trial of for previously treated patients with advanced non-small-cell lung cancer (IDEAL 1 trial). J. Clin. Oncol. 21(12), 2237-2246 (2003).
60. Kris MG, Natale RB, Herbst RS et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small-cell lung cancer: a randomized trial. JAMA 290(16), 2149-2158 (2003).